NYSE · Healthcare

GLAUKOS Corp (GKOS)

As-reported financials and recent SEC filings for GLAUKOS Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$507.4M

Net income

$-187.7M

Net margin

-37.0%

Diluted EPS

$-3.28

ROE

-28.6%

P/E (TTM)

—

Market cap

$8.48B

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$507.4M	$383.5M	$314.7M	$282.9M	$294.0M
Gross profit	$395.6M	$289.5M	$239.1M	$213.9M	$227.4M
Operating income	$-199.6M	$-122.4M	$-128.7M	$-82.3M	$-32.9M
Net income	$-187.7M	$-146.4M	$-134.7M	$-99.2M	$-49.6M
Diluted EPS	$-3.28	$-2.77	$-2.78	$-2.09	$-1.07

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

4/A2026-06-23

4/A2026-06-23

4/A2026-06-23

4/A2026-06-23

4/A2026-06-23

4/A2026-06-23

4/A2026-06-23

42026-06-18

Go deeper on GKOS

Search GLAUKOS Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.